



To: Carter BloodCare Customers
From: Hospital Relations Department
Date: January 30, 2018
Re: Circular of Information – October 2017 version

FDA accepted AABB's October 2017 Circular of Information for the Use of Human Blood and Blood Components (Circular of Information). In accordance with Food and Drug Administration (FDA) Guidance for Industry: An Acceptable Circular of Information for the Use of Human Blood and Blood Components, December 2017, Carter BloodCare is providing an update to the Circular of Information found at the link below.

<http://www.aabb.org/tm/coi/Documents/coi1017.pdf>

Please note: The following information is to be considered a part of the Circular of Information as it applies to the General Information for Whole Blood and All Blood Components, Testing of Donor Blood section.

Units labeled as negative for Zika virus RNA were tested with an Investigational nucleic acid test (NAT) and found to be nonreactive.